2SX Stock Overview
A pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
scPharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.16 |
| 52 Week High | US$5.85 |
| 52 Week Low | US$2.98 |
| Beta | 0.098 |
| 1 Month Change | -5.39% |
| 3 Month Change | -24.76% |
| 1 Year Change | -45.52% |
| 3 Year Change | -31.90% |
| 5 Year Change | -29.46% |
| Change since IPO | -65.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2SX | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 5.3% | -2.2% | -2.0% |
| 1Y | -45.5% | -15.6% | 6.9% |
Return vs Industry: 2SX underperformed the German Pharmaceuticals industry which returned -15.6% over the past year.
Return vs Market: 2SX underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| 2SX volatility | |
|---|---|
| 2SX Average Weekly Movement | 9.8% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2SX's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2SX's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 136 | John Tucker | www.scpharmaceuticals.com |
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company’s product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector.
scPharmaceuticals Inc. Fundamentals Summary
| 2SX fundamental statistics | |
|---|---|
| Market cap | €162.58m |
| Earnings (TTM) | -€76.78m |
| Revenue (TTM) | €29.02m |
5.6x
P/S Ratio-2.1x
P/E RatioIs 2SX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2SX income statement (TTM) | |
|---|---|
| Revenue | US$30.28m |
| Cost of Revenue | US$9.17m |
| Gross Profit | US$21.11m |
| Other Expenses | US$101.22m |
| Earnings | -US$80.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.60 |
| Gross Margin | 69.72% |
| Net Profit Margin | -264.60% |
| Debt/Equity Ratio | 166.4% |
How did 2SX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 06:10 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
scPharmaceuticals Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gary Nachman | BMO Capital Markets Equity Research |
| null null | BMO Capital Markets Equity Research |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |